Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment (Q37802782)

23 August 2017

Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment (English)

1 reference

23 August 2017

1 reference

Michael Hubalek

1

1 reference

23 August 2017

Christine Brunner

series ordinal

2

1 reference

23 August 2017

Karin Matthä

series ordinal

3

1 reference

23 August 2017

Christian Marth

series ordinal

4

1 reference

23 August 2017

language of work or name

1 reference

26 October 2010

1 reference

Wiener Medizinische Wochenschrift

23 August 2017

1 reference

23 August 2017

160

1 reference

23 August 2017

19-20

1 reference

23 August 2017

506-512

1 reference

https://scigraph.springernature.com/pub.10.1007/s10354-010-0838-6

23 August 2017

0 references

cites work

Biology of HER2 and its importance in breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Serum HER-2/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Target-based therapies in breast cancer: current status and future perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10354-010-0838-6

The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20972709

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20972709

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20972709

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S10354-010-0838-6

1 reference

23 August 2017

1 reference